IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials

针对高优先级 HIV-1 亚型的 IPDA 使全球根除试验成为可能

• 批准号: 10215310
• 负责人: GREGORY LAIRD
• 金额: $ 30万
• 依托单位: ACCELEVIR DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10215310
• 关键词: Base Sequence; Biological Assay; Clinical; Clinical Research; Clinical Trials; DNA; Detection; Goals; HIV; HIV Infections; HIV-1; Individual; Intervention; Monitor; Proviruses; Sampling; Testing; analytical tool; antiretroviral therapy; design; latent HIV reservoir; memory CD4 T lymphocyte; programs; prospective

Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir: Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral DNA within long-lived memory CD4+ T cells. This replication-competent HIV reservoir constitutes the primary barrier for curing HIV infection. The overall goal of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. Specifically, the assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and if successful, in prospective clinical trials.

基于序列的测定方法来量化复制能力的HIV储量：尽管有效的抗逆转录病毒疗法（ART），在所有受感染的个体中，HIV-1仍然是长期记忆CD4+ T细胞中前病毒DNA。这种复制能力的HIV储量构成了治愈HIV感染的主要障碍。该计划的总体目标是开发和商业化基于序列的HIV水库分析，以进行临床HIV治疗干预措施。具体而言，该测定应被设计为一种分析工具，以监测临床研究中复制能力的HIV储量的大小，如果成功，则在前瞻性临床试验中。